Professor Emeritus

Ian Tannock

PhD, London, MD, Pennsylvania

Princess Margaret Cancer Centre
610 University Avenue, Room 5-208, Toronto, Ontario Canada M5G 2M9
Not Accepting New Students/Researchers


Dr. Tannock is Emeritus Professor of Medicine and Medical Biophysics at Princess Margaret Cancer Centre and University of Toronto. He obtained his PhD from the Institute of Cancer Research, London University, England and his MD at University of Pennsylvania, Philadelphia, USA. His clinical expertise is in GU and breast cancer. His research investigated methods related to cancer clinical trials, and he chaired trials for men with metastatic prostate cancer that led to licencing of drugs that are used worldwide for this disease. Dr. Tannock is an editor of the Basic Science of Oncology textbook, now in its 6th edition (2021), that is used by trainees in all branches of oncology.

Dr. Tannock was a member of the Board of Directors of ASCO from 2001-2004. He chaired (2018-2020) the ASCO working group that organizes International Clinical Trials Workshops and has taught extensively in low and middle-income countries.  He received the alumnus award from M.D. Anderson Hospital, Houston, USA (1989), the Warwick Prize from the National Cancer Institute of Canada (2003), the ESMO award (2012) and the ASCO Allen Lichter award for leadership and innovation (2019). He chaired the EORTC scientific audit committee between 2009 and 2016 and was then a member of the EORTC Board. He holds honorary degrees (DSc) from London University, UK (2009) and the Universidad de la Republica, Uruguay (2020). Dr. Tannock was appointed to the Order of Canada in December 2013.

Since retiring from active practice and lab-based research in 2014, Dr Tannock teaches both locally and internationally, and authors papers relating to clinical trial  methodology. He mentors young oncologists in low and middle-income countries (LMICs) including India, Nepal and Vietnam. He chairs the Board of the Optimal Cancer Care Alliance, which is a volunteer organization that aims to facilitate dose finding trials of anticancer agents, which are often approved at higher that maximally active doses, and thereby to reduce cost and improve global access to effective cancer treatment.

Recent Publications